Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma

Brain Pathology

Volumn 26, Issue 4, 2016, Pages 517-522

  Oh, Ji Eun ^a   Ohta, Takashi ^a,b   Nonoguchi, Naosuke ^a,c   Satomi, Kaishi ^a   Capper, David ^d   Pierscianek, Daniela ^a,e   Sure, Ulrich ^e   Vital, Anne ^f   Paulus, Werner ^g   Mittelbronn, Michel ^h   Antonelli, Manila ⁱ   Kleihues, Paul ^j   Giangaspero, Felice ^i,k   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h GOETHE UNIVERSITY   (Germany)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF ZURICH   (Switzerland)

^k IRCCS NEUROMED   (Italy)

more..

Author keywords

10q; 19q; giant cell glioblastoma; gliosarcoma; IDH mutation; TERT mutation

Indexed keywords

ARTICLE; CANCER GENETICS; CDKN2A GENE; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 7; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GIANT CELL GLIOBLASTOMA; GLIOBLASTOMA; GLIOSARCOMA; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; IMMUNOHISTOCHEMISTRY; MONOSOMY; ONCOGENE; PROMOTER REGION; TERT GENE; TRISOMY;

EID: 84978522772     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12328     Document Type: Article

References (37)

1. Actor B, Cobbers JM, Buschges R, Wolter M, Knobbe CB, Reifenberger G, Weber RG (2002) Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 34:416–427.
2. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276.
3. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597–602.
4. Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME (1995) Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells. J Neuropathol Exp Neurol 54:651–656.
5. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W et al (2010) The prognostic IDH1 (R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119:487–494.
6. Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, Kirchhof A et al (1996) The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J Neuropathol Exp Neurol 55:973–981.
7. Brat DJ, Seiferheld WF, Perry A, Hammond EH, Murray KJ, Schulsinger AR, Mehta MP et al (2004) Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro Oncol 6:96–103.
8. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477
9. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404
10. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508.
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:l1.
12. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11:341–347
13. Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH (2012) Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 107:643–650
14. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, Fleming A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625.
15. Lotsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G et al (2013) Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol 15:423–432
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (eds) (2007) WHO Classification of Tumours of the Central Nervous System. IARC: Lyon
17. Martinez R, Roggendorf W, Baretton G, Klein R, Toedt G, Lichter P, Schackert G et al (2007) Cytogenetic and molecular genetic analyses of giant cell glioblastoma multiforme reveal distinct profiles in giant cell and non-giant cell subpopulations. Cancer Genet Cytogenet 175:26–34
18. Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Bostrom J, Wiestler OD, Louis DN et al (1997) Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151:853–857
19. Muller A, Holzmann K, Kestler HA (2007) Visualization of genomic aberrations using Affymetrix SNP arrays. Bioinformatics 23:496–497
20. Nagaishi M, Kim YH, Mittelbronn M, Giangaspero F, Paulus W, Brokinkel B, Vital A et al (2012) Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma. Am J Pathol 180:1816–1823
21. Nagaishi M, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato Y, Giangaspero F et al (2012) Transcriptional factors for epithelial-mesenchymal transition are associated with mesenchymal differentiation in gliosarcoma. Brain Pathol 22:670–676
22. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253–1262
23. Nobusawa S, Lachuer J, Wierinckx A, Kim YH, Huang J, Legras C, Kleihues P et al (2010) Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol 20:936–944
24. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007
25. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931–937
26. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899
27. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453
28. Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764–772
29. Ohta T, Kim YH, Oh JE, Satomi K, Nonoguchi N, Keyvani K, Pierscianek D et al (2014) Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas. J Neuropathol Exp Neurol 73:908–915
30. Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H (1999) Genetic profile of the giant cell glioblastoma. Lab Invest 79:123–129
31. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H (2000) Genetic profile of gliosarcomas. Am J Pathol 156:425–432
32. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, Sahm F et al (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol 129:867–873
33. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD et al (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328
34. Temme A, Geiger KD, Wiedemuth R, Conseur K, Pietsch T, Felsberg J, Reifenberger G et al (2010) Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. J Neuropathol Exp Neurol 69:632–642
35. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153
36. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von DA, Pfister SM, Platten M et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451
37. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773.